Clearside Biomedical Added to the Nasdaq Biotechnology Index
December 13 2021 - 4:05PM
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that the Company will be added to the Nasdaq Biotechnology Index
(Nasdaq: NBI), effective prior to market open on Monday, December
20, 2021.
The Nasdaq Biotechnology Index is designed to
track the performance of a set of securities listed on The Nasdaq
Stock Market® (Nasdaq®) that are classified as either biotechnology
or pharmaceutical according to the Industry Classification
Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under
a modified capitalization-weighted methodology. Companies in the
Nasdaq Biotechnology Index must meet eligibility requirements,
including minimum market capitalization, average daily trading
volume and seasoning as a public company, among other criteria.
Nasdaq selects constituents once annually in December.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
proprietary SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector and strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. Clearside’s first product, XIPERE™
(triamcinolone acetonide injectable suspension) for suprachoroidal
use, was approved by the U.S. Food and Drug Administration in
October 2021. For more information, please visit
www.clearsidebio.com.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2023 to Apr 2024